PROCHLORPERAZINE SUPPOSITORIES USP, 25mg
Prochlorperazine is a clear, pale yellow, viscous liquid. It is sensitive to light, very slightly soluble in water, freely soluble in alcohol, in chloroform, and in ether. Each suppository, for rectal administration, contains 25 mg of prochlorperazine; with glycerin, glyceryl monopalmitate, glyceryl monostearate, hydrogenated coconut oil fatty acids and hydrogenated palm kernel oil fatty acids.
Prochlorperazine 25mg suppositories are indicated in the control of severe nausea and vomiting in adults.
Media Articles Related to Compro (Prochlorperazine Rectal)
PTSD increases risk for cardiac ischemia
Source: Anxiety / Stress News From Medical News Today [2013.12.04]
There is growing concern that long-term untreated post-traumatic stress disorder (PTSD) symptoms may increase the risk of developing a number of medical problems, particularly compromised cardiovascular health.Heart disease remains the leading cause of death worldwide, according to the World Health Organization.
Tailored pre-transplant therapy boosts survival rate in rare immune deficiency
Source: Transplants / Organ Donations News From Medical News Today [2013.11.14]
Chronic Granulomatous Disease is a rare immune deficiency that seriously compromises organ function and is life-threatening, with 20-30 per cent of patients dying within the first two decades of life.
Actelion announces U.S. commercial availability of OPSUMIT (macitentan)
Source: Hypertension News From Medical News Today [2013.11.06]
Actelion (SIX: ATLN) has announced the commercial availability of OPSUMIT® (macitentan) 10mg, an oral, dual endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. PAH is a chronic, life-threatening disorder that can severely compromise the function of the lungs and heart. The U.S.
Communication Between Bacteria Helps Them Resist Antibiotics
Source: Cystic Fibrosis News From Medical News Today [2013.07.06]
New research from Western University unravels a novel means of communication that allows bacteria such as Burkholderia cenocepacia (B. cenocepacia) to resist antibiotic treatment. B. cenocepacia is an environmental bacterium that causes devastating infections in patients with cystic fibrosis (CF) or with compromised immune systems.Dr.
Nausea and Vomiting
Source: MedicineNet Angina Specialty [2012.04.24]
Title: Nausea and Vomiting
Category: Diseases and Conditions
Created: 1/31/2005 8:21:00 AM
Last Editorial Review: 4/24/2012 12:00:00 AM
Published Studies Related to Compro (Prochlorperazine Rectal)
Indomethacin/prochlorperazine/caffeine: a review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache. [2011.04.01]
The indomethacin/prochlorperazine/caffeine fixed combination (Difmetre(R)) combines the NSAID indomethacin with the phenothiazine antiemetic prochlorperazine and caffeine. It is currently available as two oral (effervescent tablet and coated tablet) and two rectal (suppository and low-dose suppository) formulations...
Clinical Trials Related to Compro (Prochlorperazine Rectal)
StaccatoŽ Prochlorperazine for Inhalation [Completed]
Staccato Prochlorperazine in Patients With Migraine Headache [Completed]
Prochlorperazine vs Imitrex for Acute Migraine in the Emergency Department [Completed]
ED patients with acute migraine will be randomized to either prochlorperazine and Bendaryl OR
imitrex. VAS for pain will be monitored, along with side effects. Primary outcome measure is
improvement in pain scales between the groups.
Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department [Recruiting]
This study will compare the effect of prochlorperazine and ondansetron for the treatment of
nausea and vomiting in the emergency department.
StaccatoŽ Prochlorperazine for Inhalation in Migraine [Completed]
Staccato Prochlorperazine is being developed to treat patients suffering from acute migraine
headaches. In October 2005, we completed a 75 patient, multi-center, double-blind
placebo-controlled Phase 2A clinical trial in patients suffering from moderate to severe
acute migraine headaches. This Phase 2B clinical trial of Staccato Prochlorperazine has been
initiated to assess the efficacy and safety in outpatients with migraine headache with or